Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Torbenson MS, Ng IOL, Park YN, Roncalli M, Sakamato M. WHO Classification of Digestive System Tumor. 5th ed. Geneva, Switzerland: World Health Organization; 2019:229–239.
   Google Scholar
• MacSween RNM, Burt AD, Portmann B, Ferrell LD. MacSween’s Pathology of the Liver. 6th ed. Edinburgh: Churchill Livingstone; 2011.
   Google Scholar
• Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738. PMID: 28532995. doi:10.1016/j.jhep.2017.05.014
   PubMed Web of Science ®Google Scholar
• Ziol M, Pote N, Amaddeo G, et al. Macrotrabecular- massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology. 2018;68(1):103–112. PMID: 29281854. doi:10.1002/hep.29762
   PubMed Web of Science ®Google Scholar
• Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular carcinoma. Am J Surg Pathol. 2019;43(7):943–948. PMID: 31135484. doi:10.1097/PAS.0000000000001289
   PubMed Web of Science ®Google Scholar
• Renne SL, Woo HY, Allegra S, et al. Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology. 2020;71(1):183–195. PMID: 31206715. doi:10.1002/hep.30814
   PubMed Web of Science ®Google Scholar
• Liu LL, Zhang SW, Chao X, et al. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. 2020;70:417–429. PMID: 32770259. doi:10.1007/s00262-020-02691-9
   PubMed Web of Science ®Google Scholar
• Calderaro J, Meunier L, Nguyen CT, et al. ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma. Clin Cancer Res. 2019;25(19):5859–5865. doi:10.1158/1078-0432.CCR-19-0859
   PubMed Web of Science ®Google Scholar
• Mulé S, GallettoPregliasco A, Tenenhaus A, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology. 2020;295(3):562–571. PMID: 32228294. doi:10.1148/radiol.2020192230
   PubMed Web of Science ®Google Scholar
• Yang SL, Liu LP, Yang S, et al. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103(6):716–724. PMID: 26996727. doi:10.1002/bjs.10093
   PubMed Web of Science ®Google Scholar
• Gurakar A, Ma M, Garonzik-Wang J, et al. Clinicopathological distinction of low-AFP-secreting vs. high-AFP-secreting hepatocellular carcinomas. Ann Hepatol. 2018;17(6):1052–1066. doi:10.5604/01.3001.0012.7206
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Shan Y, et al. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-based nomogram model to predict tumor recurrence of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1355–1365. doi:10.2147/JHC.S339707
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Yang Y, et al. Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma. Sci Rep. 2021 Jul 7;11(1):13999. doi:10.1038/s41598-021-93528-7
   Google Scholar
• Hsiang CW, Huang WY, Yang JF, et al. Dynamic changes in neutrophil-to-lymphocyte ratio are associated with survival and liver toxicity following stereotactic body radiotherapy for hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1299–1309. doi:10.2147/JHC.S334933
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574. doi:10.1177/0272989X0629536120
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Saville BR, Lewis RJ. Decision curve analysis. JAMA. 2015;313:409–410. doi:10.1001/jama.2015.37
   PubMed Web of Science ®Google Scholar
• Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–630. doi:10.1016/j.jhep.2019.06.001
   PubMed Web of Science ®Google Scholar
• Wei J, Jiang H, Zeng M, et al. Prediction of microvascular invasion in hepatocellular carcinoma via deep learning: a multi-center and prospective validation study. Cancers. 2021;13(10):2368. doi:10.3390/cancers13102368
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Te HS, Verna EC, et al. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2021;7(1):e638. doi:10.1097/TXD.0000000000001086
   PubMed Web of Science ®Google Scholar
• Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564–571. doi:10.1097/SLA.0000000000003268
   PubMed Web of Science ®Google Scholar
• Urebayashi Y, Matsuda K, Ueno A, et al. Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology. 2022;75(5):1139–1153. doi:10.1002/hep.32201
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994;e983; quiz e914–e985. doi:10.1053/j.gastro.2012.05.052
   PubMed Web of Science ®Google Scholar
• Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49:832–838. doi:10.1002/hep.22693
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7:12870. doi:10.1038/s41598-017-12834-1
   PubMed Web of Science ®Google Scholar
• Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 2013;11:212. PMID: 23981851; PMCID: PMC3844510. doi:10.1186/1477-7819-11-212
   PubMed Web of Science ®Google Scholar
• Tyson GL, Duan Z, Kramer JR, et al. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9(11):989–994. PMID: 21820396; PMCID: PMC3200479. doi:10.1016/j.cgh.2011.07.026
   PubMed Web of Science ®Google Scholar
• Witjes CD, IJzermans JN, van der Eijk AA, et al. Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients. Neth J Med. 2011;69(11):508–513. PMID: 22279629.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang SB, Chen SG, et al. Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab. 2018;64(10):1739–1747. PMID: 30336532. doi:10.7754/Clin.Lab.2018.180532
   PubMed Web of Science ®Google Scholar
• Li M, Zhao Y, Liu X, et al. Early risk warning system for distant metastasis of hepatitis B virus-associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett. 2020;19(4):3249–3257. PMID: 32256820; PMCID: PMC7074481. doi:10.3892/ol.2020.11423
   PubMed Web of Science ®Google Scholar
• Sun S, Wang X, Chen J. Using pre-treatment neutrophil-to-lymphocyte ratio to predict the prognosis of young patients with hepatocellular carcinoma implemented minimally invasive treatment. J Adolesc Young Adult Oncol. 2020; (1):85–89. PMID: 31621472. doi:10.1089/jayao.2019.0046
   PubMed Web of Science ®Google Scholar
• Cannella R, Dioguardi Burgio M, Beaufrère A, et al. Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS. JHEP Rep. 2021;3(6):100380. PMID: 34825155; PMCID: PMC8603197. doi:10.1016/j.jhepr.2021.100380
   PubMedGoogle Scholar
• Yugawa K, Maeda T, Kinjo N, et al. Prognostic impact of lymphocyte-C-reactive protein ratio in patients who underwent surgical resection for hepatocellular carcinoma. J Gastrointest Surg. 2021;26:104–112. PMID: 34258673. doi:10.1007/s11605-021-05085-z
   PubMed Web of Science ®Google Scholar
• Schöniger-Hekele M, Müller C, Kutilek M, et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48(1):103–109. PMID: 11115830; PMCID: PMC1728163. doi:10.1136/gut.48.1.103
   PubMed Web of Science ®Google Scholar
• Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58:58–64. doi:10.1016/j.jhep.2012.08.017
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553–2562.
   PubMed Web of Science ®Google Scholar